**Low IGFBP7 expression identifies a subset of breast cancers with favorable prognosis and sensitivity to IGF-1 receptor targeting with ganitumab: Data from I-SPY2 and SCAN-B**

Christopher Godina1, Michael N Pollak2, Helena Jernström1.

1 Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, SE-221 85 Lund, Sweden

2 Lady Davis Institute for Medical Research, Jewish General Hospital and Department of Oncology, McGill University, Montreal, QC, Canada

Table of Contents

Supplementary Figure Legends…………...…………………………………………………1

Supplementary Figure 1…………………...…………………………………………………2

Supplementary Figure 2…………………...…………………………………………………3

Supplementary Table 1………………………………………………………………………4

Supplementary Table 2………………………………………………………………………5

Supplementary Table 3………………………………………………………………………6

Supplementary Table 4………………………………………………………………………7

Supplementary Table 5………………………………………………………………………8

Supplementary Table S6-9 is available separately as an .xlsx file (Additional File 1).

# Supplementary figure legends

**Supplementary Figure 1.** Flowchart of included and excluded patients in SCAN-B

**Supplementary Figure 2.** *IGFBP7* expression in relation to molecular features

Pearson correlations of*IGFBP7* gene expression (continuous) and 15 gene in the IGF/Insulin pathway (INS, INSR, IRS1, IRS2, IGF1, IGF2, IGFALS, IGF1R, IGF2R, IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, and IGFBP6) in (**A**) I-SPY2, and (**B**) SCAN-B. Pearson correlations of*IGFBP7* gene expression (continuous) and the eight gene modules (Stroma, Lipid, Immune Response, Mitotic Checkpoint, Mitotic Progression, Basal, Early Response, Steroid Response) in (**C**) I-SPY2, and (**D**) SCAN-B. *IGFBP7* expression (continuous) by PAM50 subtype in (**E**) I-SPY2 and (**F**) SCAN-B. SCAN-B. *IGFBP7* expression (continuous) by receptor subtype in (**G**) I-SPY2 and (**H**) SCAN-B.

A screenshot of a cell phone

Description automatically generated

A collage of graphs and diagrams

Description automatically generated

| **Supplementary Table 1** Odds ratio of achieving a pCR in relation *IGFBP7* gene expression, all patients (arms) in I-SPY2 | | | | |
| --- | --- | --- | --- | --- |
|  | **IGFBP7 Continuous** | | **IGFBP7 quartiles** | |
| **Variable** | **OR**1 | **95% CI**1 | **OR**1 | **95% CI**1 |
| **IGFBP7 Continuous** | 0.99 | 0.79, 1.25 |  |  |
| **IGFBP7 Quartiles** |  |  |  |  |
| Q1 |  |  | Ref. |  |
| Q2 |  |  | 0.77 | 0.50, 1.20 |
| Q3 |  |  | 1.19 | 0.76, 1.85 |
| Q4 |  |  | 0.96 | 0.60, 1.52 |
| **HR+** | 0.72 | 0.46, 1.10 | 0.71 | 0.46, 1.09 |
| **HER2+** | 3.32 | 1.88, 5.85 | 3.34 | 1.90, 5.90 |
| **MP2** | 1.54 | 0.97, 2.46 | 1.60 | 1.00, 2.56 |
| **Immune+** | 2.89 | 2.03, 4.15 | 2.88 | 2.02, 4.14 |
| **DRD+** | 1.64 | 1.03, 2.65 | 1.69 | 1.05, 2.73 |
| **PAM50 Subtype** |  |  |  |  |
| LumA | Ref. |  | Ref. |  |
| Basal | 1.86 | 0.83, 4.21 | 1.84 | 0.82, 4.17 |
| Her2 | 3.32 | 1.70, 6.60 | 3.34 | 1.71, 6.65 |
| LumB | 1.58 | 0.86, 2.95 | 1.65 | 0.90, 3.09 |
| Normal | 2.00 | 0.59, 6.43 | 2.02 | 0.60, 6.50 |
| **Trial Arm** |  |  |  |  |
| Control | Ref. |  | Ref. |  |
| AMG386 | 2.10 | 1.19, 3.73 | 2.15 | 1.22, 3.82 |
| Ganetespib | 1.74 | 0.91, 3.28 | 1.69 | 0.89, 3.20 |
| Ganitumab + metformin | 1.76 | 0.92, 3.32 | 1.75 | 0.92, 3.30 |
| MK2206 | 1.89 | 1.01, 3.54 | 1.85 | 0.99, 3.47 |
| Neratinib | 1.98 | 1.08, 3.64 | 2.01 | 1.10, 3.70 |
| Pembrolizumab | 5.38 | 2.70, 10.8 | 5.30 | 2.66, 10.7 |
| Pertuzumab | 4.91 | 2.09, 11.8 | 5.21 | 2.20, 12.6 |
| Trastuzumab-emtansine | 3.82 | 1.65, 8.99 | 3.94 | 1.69, 9.32 |
| Carboplatin + ABT888 | 3.55 | 1.80, 7.04 | 3.56 | 1.80, 7.06 |
| 1OR = Odds Ratio, CI = Confidence Interval  Control: Paclitaxel (+Trastuzumab if HER2+) followed by doxorubicin and cyclophosphamide | | | | |

| **Supplementary Table 2.** Descriptive statistics of IGFBP7 quartiles in relation to clinicopathological characteristics in I-SPY2 | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **IGFBP7 Quartiles** | | | |
|  | All patients1 | Missing | **Q1**,  n = 2441 | **Q2**,  n = 2441 | **Q3**,  n = 2431 | **Q4**,  n = 2431 |
| **HR+** | 528 (54%) | 0 | 103 (42%) | 133 (55%) | 153 (63%) | 139 (57%) |
| **HER2+** | 244 (25%) | 0 | 35 (14%) | 71 (29%) | 65 (27%) | 73 (30%) |
| **MP2** | 476 (49%) | 0 | 168 (69%) | 128 (52%) | 97 (40%) | 83 (34%) |
| **Immune+** | 446 (46%) | 0 | 140 (57%) | 103 (42%) | 101 (42%) | 102 (42%) |
| **DRD+** | 364 (37%) | 3 | 128 (52%) | 94 (39%) | 71 (29%) | 71 (29%) |
| **PAM50 Subtype** |  | 15 |  |  |  |  |
| LumA | 172 (18%) |  | 16 (6.6%) | 36 (15%) | 57 (24%) | 63 (26%) |
| Basal | 406 (42%) |  | 154 (64%) | 100 (42%) | 82 (34%) | 70 (29%) |
| Her2 | 140 (15%) |  | 27 (11%) | 35 (15%) | 34 (14%) | 44 (18%) |
| LumB | 218 (23%) |  | 42 (17%) | 66 (28%) | 63 (26%) | 47 (20%) |
| Normal | 23 (2.4%) |  | 2 (0.8%) | 2 (0.8%) | 3 (1.3%) | 16 (6.7%) |
| **pCR** | 313 (32%) | 0 | 86 (35%) | 74 (30%) | 79 (33%) | 74 (30%) |
| **Trial Arm** |  | 0 |  |  |  |  |
| Control | 205 (21%) |  | 55 (23%) | 45 (18%) | 53 (22%) | 52 (21%) |
| AMG386 | 133 (14%) |  | 30 (12%) | 37 (15%) | 27 (11%) | 39 (16%) |
| Ganetespib | 93 (9.5%) |  | 28 (11%) | 22 (9.0%) | 27 (11%) | 16 (6.6%) |
| Ganitumab + metformin | 105 (11%) |  | 32 (13%) | 29 (12%) | 26 (11%) | 18 (7.4%) |
| MK2206 | 94 (9.7%) |  | 24 (9.8%) | 17 (7.0%) | 26 (11%) | 27 (11%) |
| Neratinib | 112 (11%) |  | 24 (9.8%) | 32 (13%) | 28 (12%) | 28 (12%) |
| Pembrolizumab | 69 (7.1%) |  | 8 (3.3%) | 11 (4.5%) | 16 (6.6%) | 34 (14%) |
| Pertuzumab | 44 (4.5%) |  | 7 (2.9%) | 19 (7.8%) | 10 (4.1%) | 8 (3.3%) |
| Trastuzumab-emtansine | 52 (5.3%) |  | 7 (2.9%) | 17 (7.0%) | 15 (6.2%) | 13 (5.3%) |
| Carboplatin + ABT888 | 67 (6.9%) |  | 29 (12%) | 15 (6.1%) | 15 (6.2%) | 8 (3.3%) |
| 1n (%)  Control: Paclitaxel (+Trastuzumab if HER2+) followed by Anthracyclines | | | | | | |

| **Supplementary Table 3.** Descriptive statistics of IGFBP7 quartiles in relation to clinicopathological characteristics in SCAN-B | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **IGFBP7 Quartiles** | | | |
|  | All patients1 | Missing | **Q1**, n = 1,3321 | **Q2**, n = 1,3321 | **Q3**, n = 1,3311 | **Q4**, N = 1,3311 |
| **Age at diagnosis, years** |  | 0 |  |  |  |  |
| -40 | 270 (5.1%) |  | 72 (5.4%) | 51 (3.8%) | 85 (6.4%) | 62 (4.7%) |
| 41-50 | 874 (16%) |  | 176 (13%) | 235 (18%) | 260 (20%) | 203 (15%) |
| 51-60 | 1,045 (20%) |  | 233 (17%) | 253 (19%) | 282 (21%) | 277 (21%) |
| 61-70 | 1,661 (31%) |  | 396 (30%) | 426 (32%) | 403 (30%) | 436 (33%) |
| 71-80 | 995 (19%) |  | 279 (21%) | 249 (19%) | 211 (16%) | 256 (19%) |
| 81- | 481 (9.0%) |  | 176 (13%) | 118 (8.9%) | 90 (6.8%) | 97 (7.3%) |
| **Invasive tumor size** (pT2/3/4) | 1,783 (35%) | 166 | 530 (41%) | 421 (32%) | 403 (31%) | 429 (33%) |
| **Lymph node status** (pN1/2/3) | 1,873 (37%) | 213 | 461 (36%) | 475 (37%) | 497 (39%) | 440 (34%) |
| **Histological type** |  | 37 |  |  |  |  |
| Ductal | 4,182 (79%) |  | 1,083 (82%) | 1,085 (82%) | 1,083 (82%) | 931 (71%) |
| Lobular | 732 (14%) |  | 108 (8.2%) | 137 (10%) | 167 (13%) | 320 (24%) |
| Other or Mixed | 375 (7.1%) |  | 131 (9.9%) | 100 (7.6%) | 77 (5.8%) | 67 (5.1%) |
| **Histological grade** |  | 382 |  |  |  |  |
| I | 791 (16%) |  | 130 (11%) | 181 (15%) | 224 (18%) | 256 (21%) |
| II | 2,443 (49%) |  | 512 (42%) | 621 (50%) | 626 (50%) | 684 (55%) |
| III | 1,710 (35%) |  | 588 (48%) | 437 (35%) | 391 (32%) | 294 (24%) |
| **ER+** | 4,497 (85%) | 49 | 1,047 (79%) | 1,138 (87%) | 1,168 (88%) | 1,144 (87%) |
| **PR+** | 3,725 (71%) | 51 | 871 (66%) | 965 (73%) | 959 (72%) | 930 (71%) |
| **HER2+** | 702 (14%) | 149 | 145 (11%) | 192 (15%) | 213 (16%) | 152 (12%) |
| **TNBC** | 525 (10%) | 278 | 208 (17%) | 117 (9.3%) | 91 (7.2%) | 109 (8.6%) |
| **Endocrine therapy** | 4,109 (78%) | 85 | 965 (74%) | 1,046 (79%) | 1,053 (81%) | 1,045 (80%) |
| **Chemotherapy** | 2,243 (43%) | 85 | 616 (47%) | 583 (44%) | 565 (43%) | 479 (36%) |
| **Trastuzumab** | 585 (11%) | 85 | 118 (9.1%) | 165 (13%) | 172 (13%) | 130 (9.9%) |
| **PAM50 Subtype** |  | 0 |  |  |  |  |
| LumA | 2,255 (42%) |  | 365 (27%) | 576 (43%) | 650 (49%) | 664 (50%) |
| Basal | 471 (8.8%) |  | 204 (15%) | 114 (8.6%) | 72 (5.4%) | 81 (6.1%) |
| Her2 | 641 (12%) |  | 131 (9.8%) | 167 (13%) | 193 (15%) | 150 (11%) |
| LumB | 1,275 (24%) |  | 574 (43%) | 391 (29%) | 224 (17%) | 86 (6.5%) |
| Normal | 684 (13%) |  | 58 (4.4%) | 84 (6.3%) | 192 (14%) | 350 (26%) |
| **PAM50 ROR** |  | 292 |  |  |  |  |
| High | 2,361 (47%) |  | 824 (66%) | 674 (54%) | 507 (40%) | 356 (28%) |
| Intermediate | 738 (15%) |  | 205 (16%) | 185 (15%) | 204 (16%) | 144 (11%) |
| Low | 1,935 (38%) |  | 219 (18%) | 399 (32%) | 554 (44%) | 763 (60%) |
| 1n (%) | | | | | | |

| **Supplementary Table 4.** *IGFBP7* (in quartiles) gene expression in relation to clinical outcome in SCAN-B | | | | |
| --- | --- | --- | --- | --- |
|  | **Recurrence-**  **free interval** | | **Distant metastasis-**  **free interval** | | |
| **Variables** | **HR**1 | **95% CI**1 | **HR**1 | **95% CI**1 | |
| **Crude** |  |  |  |  | |
| **IGFBP7 Quartiles** |  |  |  |  | |
| Q1 | Ref. |  | Ref. |  | |
| Q2 | 0.95 | 0.75, 1,21 | 0.99 | 0.76, 1,31 | |
| Q3 | 0.92 | 0.72, 1.16 | 0.93 | 0.71, 1.23 | |
| Q4 | 0.96 | 0.76, 1.22 | 1.00 | 0.77, 1.32 | |
| **Multivariable** |  |  |  |  | |
| **IGFBP7 Quartiles** |  |  |  |  | |
| Q1 | Ref. |  | Ref. |  | |
| Q2 | 1.13 | 0.87, 1.47 | 1.26 | 0.93, 1.71 | |
| Q3 | 1.20 | 0.91, 1.58 | 1.37 | 1.00, 1.89 | |
| Q4 | 1.37 | 1.04, 1.82 | 1.60 | 1.15, 2.22 | |
| **Age** (5-year bin) | 1.00 | 0.99, 1.01 | 1.01 | 1.00, 1.02 | |
| **Tumor size** (pT2/3/4) | 1.90 | 1.55, 2.32 | 2.26 | 1.78, 2.85 | |
| **Lymph node status** (pN1/2/3) | 1.31 | 1.06, 1.62 | 1.57 | 1.24, 2.01 | |
| **Grade III** | 1.27 | 0.98, 1.63 | 1.29 | 0.97, 1.73 | |
| **ER+** | 1.52 | 0.94, 2.46 | 1.06 | 0.59, 1.91 | |
| **PR+** | 0.90 | 0.69, 1.17 | 0.81 | 0.60, 1.09 | |
| **HER2+** | 1.95 | 1.27, 2.99 | 2.09 | 1.32, 3.30 | |
| **PAM50 ROR High** | 2.20 | 1.61, 3.01 | 2.47 | 1.71, 3.58 | |
| **PAM50 subtype** |  |  |  |  | |
| LumA | Ref. |  | Ref. |  | |
| Basal | 1.53 | 0.91, 2.58 | 1.68 | 0.93, 3.04 | |
| Her2 | 1.60 | 1.06, 2.42 | 1.58 | 0.99, 2.53 | |
| LumB | 1.21 | 0.87, 1.70 | 1.29 | 0.87, 1.90 | |
| Normal | 1.40 | 0.99, 1.97 | 1.47 | 0.97, 2.23 | |
| **Chemotherapy** | 0.77 | 0.59, 1.00 | 0.91 | 0.67, 1.24 | |
| **Endocrine therapy** | 0.45 | 0.32, 0.63 | 0.75 | 0.46, 1.21 | |
| **Trastuzumab** | 0.30 | 0.18, 0.51 | 0.29 | 0.16, 0.51 | |

| **Supplementary Table 5.** *IGFBP7* (continuous) gene expression in relation to clinical outcome in SCAN-B | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Recurrence-**  **free interval** | | | **Distant metastasis-**  **free interval** | |
| **Variables** | **HR**1 | **95% CI**1 | **HR**1 | | **95% CI**1 |
| **Crude** |  |  |  | |  |
| **IGFBP7 Continuous** | 1.01 | 0.88, 1.16 | 1.02 | | 0.87, 1.20 |
| **Multivariable** |  |  |  | |  |
| **IGFBP7 Continuous** | 1.29 | 1.09, 1.53 | 1.41 | | 1.16, 1.73 |
| **Age** (5-year bin) | 1.00 | 0.99, 1.01 | 1.01 | | 1.00, 1.02 |
| **Tumor size** (pT2/3/4) | 1.92 | 1.57, 2.34 | 2.27 | | 1.80, 2.87 |
| **Lymph node status** (pN1/2/3) | 1.30 | 1.05, 1.60 | 1.56 | | 1.23, 1.99 |
| **Grade III** | 1.27 | 0.99, 1.63 | 1.29 | | 0.97, 1.73 |
| **ER+** | 1.52 | 0.94, 2.46 | 1.05 | | 0.58, 1.91 |
| **PR+** | 0.90 | 0.69, 1.18 | 0.81 | | 0.61, 1.09 |
| **HER2+** | 1.92 | 1.25, 2.93 | 2.07 | | 1.31, 3.26 |
| **PAM50 ROR High** | 2.23 | 1.63, 3.05 | 2.52 | | 1.74, 3.64 |
| **PAM50 subtype** |  |  |  | |  |
| LumA | Ref. |  | Ref. | |  |
| Basal | 1.57 | 0.93, 2.65 | 1.72 | | 0.95, 3.11 |
| Her2 | 1.61 | 1.07, 2.43 | 1.59 | | 0.99, 2.55 |
| LumB | 1.24 | 0.89, 1.73 | 1.31 | | 0.89, 1.93 |
| Normal | 1.37 | 0.97, 1.93 | 1.43 | | 0.94, 2.17 |
| **Chemotherapy** | 0.77 | 0.59, 1.00 | 0.91 | | 0.67, 1.24 |
| **Endocrine therapy** | 0.45 | 0.32, 0.63 | 0.75 | | 0.46, 1.21 |
| **Trastuzumab** | 0.31 | 0.18, 0.52 | 0.29 | | 0.17, 0.52 |